Expert validation on proposed framework for differentiated HTA criteria for rare disease drugs in Brazil (2023)
- Authors:
- USP affiliated authors: AGUIAR, PATRICIA MELO - FCF ; BIGLIA, LUIZA VASCONCELOS - FCF
- Unidade: FCF
- DOI: 10.1016/j.jval.2023.09.1783
- Subjects: DOENÇAS RARAS; MEDICAMENTO
- Language: Inglês
- Imprenta:
- Source:
- Título: Value in Health
- ISSN: 1098-3015
- Volume/Número/Paginação/Ano: v. 26, n. 12, Suppl., p. S337, 2023
- Conference titles: ISPOR Europe
- Este periódico é de acesso aberto
- Este artigo NÃO é de acesso aberto
-
ABNT
BIGLIA, Luiza Vasconcelos et al. Expert validation on proposed framework for differentiated HTA criteria for rare disease drugs in Brazil. Value in Health. Amsterdam: Faculdade de Ciências Farmacêuticas, Universidade de São Paulo. Disponível em: https://doi.org/10.1016/j.jval.2023.09.1783. Acesso em: 17 fev. 2026. , 2023 -
APA
Biglia, L. V., Felippini, A., Ribeiro, T. B., Lima, T. D. M., & Aguiar, P. M. (2023). Expert validation on proposed framework for differentiated HTA criteria for rare disease drugs in Brazil. Value in Health. Amsterdam: Faculdade de Ciências Farmacêuticas, Universidade de São Paulo. doi:10.1016/j.jval.2023.09.1783 -
NLM
Biglia LV, Felippini A, Ribeiro TB, Lima TDM, Aguiar PM. Expert validation on proposed framework for differentiated HTA criteria for rare disease drugs in Brazil [Internet]. Value in Health. 2023 ; 26( 12): S337.[citado 2026 fev. 17 ] Available from: https://doi.org/10.1016/j.jval.2023.09.1783 -
Vancouver
Biglia LV, Felippini A, Ribeiro TB, Lima TDM, Aguiar PM. Expert validation on proposed framework for differentiated HTA criteria for rare disease drugs in Brazil [Internet]. Value in Health. 2023 ; 26( 12): S337.[citado 2026 fev. 17 ] Available from: https://doi.org/10.1016/j.jval.2023.09.1783 - HTA criteria adopted in different models of public healthcare systems for orphan drugs: a scoping review
- Desenvolvimento e validação de critérios diferenciados para Avaliação de Tecnologias em Saúde (ATS) de doenças raras no SUS
- Economic evaluations on the use of aripiprazole for patients with schizophrenia: a systematic review
- Prevalence of depression and anxiety among pharmacy students: a systematic review
- Does sex affect the efficacy, safety, and quality of life outcomes for patients using angiotensin receptor neprilysin inhibitor, soluble guanylate cyclase stimulators, and cardiac myosin activators in heart failure? a systematic review
- Pharmacist interventions in schizophrenia and bipolar affective disorder: a systematic review and meta-analysis
- Use of medications by patients who are Deaf or Hard of Hearing: Reflections for the promotion of rational use
- Colaboração médico-farmacêutico no manejo de pacientes com diabetes mellitus tipo 2: expectativas e resultados
- Development of a value assessment framework for Health Technology Assessment in rare diseases drugs: insights from a Delphi study in Brazil
- Pharmacist participated medication review in different practice settings: service or intervention? an overview of systematic reviews
Informações sobre o DOI: 10.1016/j.jval.2023.09.1783 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
